ScreenerHero

MYGN Myriad Genetics, Inc.

NAS · US · Healthcare · Diagnostics & Research · myriad.com
4.280USD0.00%Mkt Cap: 409.38M $P/E: —

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides …

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap409.38M USD
Enterprise Value504.68M USD
Revenue (TTM)806.60M USD
Gross Profit576.60M USD
Net Income (TTM)-365.90M USD
Revenue/Share8.61 USD
Last Price4.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.7K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.35
PEG1.24
EV/EBITDA-12.52
EV/Revenue0.63
P/S0.51
P/B1.35
EPS (TTM)-1.18
EPS (Forward)-0.58
52W Range
2.74026% of range8.590
52W High8.590 USD
52W Low2.740 USD
Profitability
Gross Margin69.93%
Oper. Margin-20.40%
EBITDA Margin-5.00%
Profit Margin-44.38%
ROE-99.43%
ROA-51.78%
Growth
Revenue Growth-10.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.80M USD
CapEx (TTM)27.40M USD
FCF Margin2.25%
FCF Yield4.44%
Net Debt95.30M USD
Net Debt/EBITDA-2.36
Balance Sheet
Debt/Equity0.57
Current Ratio2.21
Quick Ratio1.72
Book Value/Sh3.18 USD
Cash/Share1.20 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateMar 26, 2009
Analyst Consensus
Rating3.2 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.913 USD
Upside (mean)-8.6%
Target Range2.000 USD – 8.000 USD
2.000-8.6% to mean8.000
# Analysts8
Ownership
Shares Out.95.65M
Float79.30M
Insiders4.01%
Institutions97.09%
Short Interest
Short Ratio5.0d
Short % Float10.01%
Short % Out.9.77%
Shares Short9.35M
Short (prev mo.)7.68M
Technical
SMA 503.617 (+18.3%)
SMA 2004.724 (-9.4%)
Beta1.64
S&P 52W Chg16.45%
Avg Vol (30d)1.85M
Avg Vol (10d)1.81M
Technical Indicators
RSI (14)58.3
MACD0.1835
MACD Signal0.1298
MACD Hist.+0.0537
BB Upper4.797 USD
BB Middle3.978 USD
BB Lower3.159 USD
BB Width41.17%
ATR (14)0.2718 USD
Vol Ratio (20d)0.81x